---
title: "TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281589536.md"
description: "The Schall Law Firm is investigating claims on behalf of investors of Theravance Biopharma, Inc. (NASDAQ: TBPH) for potential violations of securities laws. The investigation centers on whether the company made false or misleading statements and failed to disclose critical information. Theravance reportedly incurred significant operational expenses during its CYPRESS trial, which ultimately failed. Shareholders who suffered losses are encouraged to participate in the investigation and can contact the Schall Law Firm for more information."
datetime: "2026-04-03T00:55:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281589536.md)
  - [en](https://longbridge.com/en/news/281589536.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281589536.md)
---

# TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm

**TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm**

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Theravance Biopharma, Inc. (“Theravance” or “the Company”) (NASDAQ: TBPH) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Theravance reported spending millions of dollars on operations expenses while its CYPRESS trial was in the enrollment phase, representing a major cash burn on a high-risk program. The Company’s trial ultimately failed.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

The Schall Law Firm  
Brian Schall, Esq.  
310-301-3335  
info@schallfirm.com  
www.schallfirm.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20260402251057/en/

### Related Stocks

- [TBPH.US](https://longbridge.com/en/quote/TBPH.US.md)

## Related News & Research

- [Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update | TBPH Stock News](https://longbridge.com/en/news/285551659.md)
- [Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | TBPH Stock News](https://longbridge.com/en/news/279788810.md)
- [19:06 ETUPST Investors Have Opportunity to Lead Upstart Holdings, Inc. Securities Fraud Lawsuit](https://longbridge.com/en/news/286827382.md)
- [03:15 ETCIGL, YOOV Deadline: CIGL, YOOV Investors Have Opportunity to Lead Concorde International Group Ltd. Securities Fraud Lawsuit](https://longbridge.com/en/news/287021785.md)
- [03:56 ETSTLA Investors Have Opportunity to Lead Stellantis N.V. Securities Fraud Lawsuit](https://longbridge.com/en/news/287178800.md)